{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:59:37Z","timestamp":1789617577371,"version":"build-2803163510"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is a common comorbidity of both type 1 diabetes (T1D) and type 2 diabetes (T2D) and is associated with increased mortality, end-stage kidney disease and cardiovascular disease risk. Despite standard-of-care treatment with renin\u2013angiotensin system inhibitors added to blood pressure and glycaemic control, people with CKD and T1D have a residual risk of CKD progression. Advances in therapeutic management have been limited over the past 3\u00a0decades, especially compared with CKD in T2D, for which new treatment options have emerged in the last 5\u00a0years. In this review article we discuss the similarities and differences between T1D and T2D populations with CKD, including epidemiology, pathophysiology and clinical findings. Additionally, we explore the use of albuminuria as a potential bridging biomarker to extrapolate clinical evidence from one population to the other. This concept could offer a promising strategy to narrow the gap in treatment availability between these populations and address the unmet therapeutic need in people with CKD and T1D. The FINE-ONE trial is investigating the non-steroidal mineralocorticoid receptor antagonist finerenone in a population with CKD and T1D using the change in urine albumin:creatinine ratio from baseline over 6\u00a0months as its primary endpoint and bridging biomarker. Similarities between the populations from FINE-ONE trial and FIDELITY (a pooled dataset of individuals with CKD and T2D included in two large phase 3 clinical trials of finerenone) may inform the translation of clinical evidence on finerenone from people with CKD and T2D to those with CKD and T1D.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf183","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:35:10Z","timestamp":1757417710000},"page":"556-565","source":"Crossref","is-referenced-by-count":6,"title":["Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J L","family":"Heerspink","sequence":"first","affiliation":[{"name":"Clinical Pharmacy and Pharmacology, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-7100","authenticated-orcid":false,"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Richard L. Roudebush VA Medical Center and Indiana University School of Medicine , Indianapolis, IN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-0903","authenticated-orcid":false,"given":"Antonio J","family":"Amor","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona Endocrinology and Nutrition Department, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-1277","authenticated-orcid":false,"given":"Jesper N","family":"Bech","sequence":"additional","affiliation":[{"name":"G\u00f8dstrup Hospital University Clinic in Nephrology and Hypertension and Department of Endocrinology, , Herning ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Health Network, Toronto General Hospital, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1093-7724","authenticated-orcid":false,"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, ASST Fatebenefratelli-Sacco, Milan and Universita degli Studi di Milano , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-4294","authenticated-orcid":false,"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-7482","authenticated-orcid":false,"given":"Karoline","family":"Schousboe","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Odense, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-8326","authenticated-orcid":false,"given":"Nicholas M","family":"Selby","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research and Innovation, Academic Unit for Translational Medical Sciences, University of Nottingham, Royal Derby Hospital Campus , Derby ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-8683","authenticated-orcid":false,"given":"Stefan D","family":"Anker","sequence":"additional","affiliation":[{"name":"German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-0332","authenticated-orcid":false,"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens Department of Cardiology, , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan School of Medicine Department of Medicine, , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6278-7951","authenticated-orcid":false,"given":"Luis M","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12 , Madrid ,","place":["Spain"]},{"name":"CIBER-CV, Hospital Universitario \u00a0 12 de Octubre, Madrid ,","place":["Spain"]},{"name":"Faculty of Sport Sciences, European University of Madrid , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4253-6313","authenticated-orcid":false,"given":"Robert","family":"Lawatscheck","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-9535","authenticated-orcid":false,"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[{"name":"Cardiology and Nephrology Clinical Development, Bayer AG , Wuppertal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Russell","sequence":"additional","affiliation":[{"name":"Bayer PLC , Reading ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7787-5662","authenticated-orcid":false,"given":"Patrick","family":"Schloemer","sequence":"additional","affiliation":[{"name":"Clinical Statistics and Analytics, Bayer AG , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-6521","authenticated-orcid":false,"given":"Janet B","family":"McGill","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2026022705015891400_bib1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025","edition":"11th edn."},{"key":"2026022705015891400_bib2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022705015891400_bib3","first-page":"101130","article-title":"Prevalence and outcomes of chronic kidney disease in type 1 diabetes","volume":"47","author":"Tuttle","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"2026022705015891400_bib4","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2026022705015891400_bib5","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib6","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib8","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1016\/j.ekir.2024.09.010","article-title":"Prognosis for type 1 diabetes with diabetic nephropathy between 2000 and 2020 \u2013 changes in kidney function decline over time and development of cardiovascular disease, kidney failure, and mortality","volume":"9","author":"Poulsen","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026022705015891400_bib9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"2026022705015891400_bib10","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2337\/dc18-2062","article-title":"Risk factors for kidney disease in type 1 diabetes","volume":"42","author":"Perkins","year":"2019","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib11","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2337\/dc24-0335","article-title":"Prevalence of chronic kidney disease in type 1 diabetes among adults in the U.S","volume":"47","author":"Rossing","year":"2024","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib12","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Marx-Sch\u00fctt","year":"2025","journal-title":"Eur Heart J"},{"key":"2026022705015891400_bib13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2337\/dc20-2839","article-title":"Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study","volume":"44","author":"Krist\u00f3fi","year":"2021","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib14","doi-asserted-by":"publisher","first-page":"101429","DOI":"10.1016\/j.diabet.2023.101429","article-title":"Prevalence and incidence of cardiovascular and renal diseases in type 1 compared with type 2 diabetes: a nationwide French observational study of hospitalized patients","volume":"49","author":"Ducluzeau","year":"2023","journal-title":"Diabetes Metab"},{"key":"2026022705015891400_bib15","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jacc.2024.06.024","article-title":"Cardiorenal outcomes in middle-aged and older adults with type 1 and type 2 diabetes","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026022705015891400_bib16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.kint.2022.05.012","article-title":"Molecular mechanisms and therapeutic targets for diabetic kidney disease","volume":"102","author":"Tuttle","year":"2022","journal-title":"Kidney Int"},{"key":"2026022705015891400_bib17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000528783","article-title":"Mineralocorticoid receptor-associated mechanisms in diabetic kidney disease and clinical significance of mineralocorticoid receptor antagonists","volume":"54","author":"Mende","year":"2023","journal-title":"Am J Nephrol"},{"key":"2026022705015891400_bib18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026022705015891400_bib19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"key":"2026022705015891400_bib20","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.2337\/dci25-0028","article-title":"Kidney disease: the forgotten legacy of type 1 diabetes","volume":"48","author":"Thomas","year":"2025","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib21","first-page":"163","article-title":"Endothelial glycocalyx restoration by growth factors in diabetic nephropathy","volume":"56","author":"Desideri","year":"2019","journal-title":"Biorheology"},{"key":"2026022705015891400_bib22","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3390\/cells11182917","article-title":"Diabetic proteinuria revisited: updated physiologic perspectives","volume":"11","author":"Heyman","year":"2022","journal-title":"Cells"},{"key":"2026022705015891400_bib23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/sj.ki.5001704","article-title":"Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells","volume":"70","author":"Ohse","year":"2006","journal-title":"Kidney Int"},{"key":"2026022705015891400_bib24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026022705015891400_bib26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026022705015891400_bib27","doi-asserted-by":"publisher","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026022705015891400_bib28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib32","article-title":"Jardiance\u00ae (empagliflozin) prescribing information","author":"Boehringer Ingelheim","year":"2021"},{"key":"2026022705015891400_bib33","article-title":"Farxiga\u00ae (dapagliflozin) prescribing information","author":"AstraZeneca Pharmaceuticals LP","year":"2021"},{"key":"2026022705015891400_bib34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","article-title":"People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action","volume":"11","author":"Heerspink","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022705015891400_bib35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s43441-022-00445-6","article-title":"Innovations in pediatric therapeutics development: principles for the use of bridging biomarkers in pediatric extrapolation","volume":"57","author":"Fleming","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"2026022705015891400_bib36","article-title":"Drug Development Tool (DDT) Qualification Programs","author":"U.S. Food and Drug Administration","year":"2025"},{"key":"2026022705015891400_bib37","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"2026022705015891400_bib38","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","article-title":"Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria","volume":"42","author":"Vistisen","year":"2019","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib39","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study","volume":"11","author":"de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022705015891400_bib40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022705015891400_bib41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026022705015891400_bib42","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026022705015891400_bib43","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026022705015891400_bib45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022705015891400_bib46","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s13300-023-01523-0","article-title":"The effect of sodium-glucose cotransporter inhibitors on renal function as adjunctive to insulin in adults with type 1 diabetes: an updated multilevel meta-analysis of randomized controlled trials","volume":"15","author":"Karakasis","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026022705015891400_bib47","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib48","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s13300-021-01169-w","article-title":"Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes","volume":"12","author":"Dena","year":"2021","journal-title":"Diabetes Ther"},{"issue":"Suppl 1","key":"2026022705015891400_bib49","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026022705015891400_bib50","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"key":"2026022705015891400_bib51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026022705015891400_bib52","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"key":"2026022705015891400_bib53","doi-asserted-by":"publisher","first-page":"e030131","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf183\/64246918\/gfaf183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/556\/64246918\/gfaf183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/556\/64246918\/gfaf183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:02:06Z","timestamp":1772186526000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/3\/556\/8251659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,15]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf183","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,15]]}}}